Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents

25 May 2018

Abstract excerpt

HIV latency in resting CD4+ T cell represents a key barrier preventing cure of the infection with antiretroviral drugs alone. Latency reversing agents (LRAs) can activate HIV expression in latently infected cells, potentially leading to their elimination through virus-mediated cytopathic effects, host immune responses, and/or therapeutic strategies targeting cells actively expressing virus. We have recently...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV/AIDS drug development and treatment
Share to HIV/AIDS Research and Interventions
Share to HIV Research and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29800728
DOI: 10.1016/j.virol.2018.05.006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agentsPMID 29800728Read ↗

An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene ExpressionSemantic proximity Read ↗

Synthesis and evaluation of designed PKC modulators for enhanced cancer immunotherapySemantic proximity Read ↗

Simplified Bryostatin Analogues Protect Cells from Chikungunya Virus-Induced Cell DeathSemantic proximity Read ↗

Selective Class I HDAC Inhibitors Based on Aryl Ketone Zinc Binding Induce HIV-1 Protein for ClearanceSemantic proximity Read ↗

Small Molecule Inhibitors of BAF; A Promising Family of Compounds in HIV-1 Latency ReversalSemantic proximity Read ↗

Unlocking the Drug Potential of the Bryostatin Family: Recent Advances in Product Synthesis and Biomedical ApplicationsSemantic proximity Read ↗

Targeting NF-κB Signaling with Protein Kinase C Agonists As an Emerging Strategy for Combating HIV LatencySemantic proximity Read ↗

Diversity of small molecule HIV‐1 latency reversing agents identified in low‐ and high‐throughput small molecule screensSemantic proximity Read ↗

GS-9822, a Preclinical LEDGIN Candidate, Displays a Block-and-Lock Phenotype in Cell CultureSemantic proximity Read ↗

Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivoSemantic proximity Read ↗

Activation of Latent HIV-1 Expression by Protein Kinase C Agonists. A Novel Therapeutic Approach to Eradicate HIV-1 ReservoirsSemantic proximity Read ↗

BI-2536 and BI-6727, dual Polo-like kinase/bromodomain inhibitors, effectively reactivate latent HIV-1Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.